Navigation Links
ViroPharma to Release 2011 First Quarter Financial Results On April 28, 2011

EXTON, Pa., April 20, 2011 /PRNewswire/ -- ViroPharma Incorporated's (Nasdaq: VPHM) first quarter financial results for 2011 are expected to be released on Thursday, April 28, 2011 before the open of the U.S. financial markets.

The company will host a conference call and live audio webcast at 9:00 a.m. Eastern Time on the same day.  During the conference call, ViroPharma management will discuss the 2011 first quarter financial results and other business.

The press release and the live webcast of the conference call will be accessible via ViroPharma's corporate website at  An audio archive will be available at the same address until May 18, 2011.  To participate in the conference call, please dial (888) 299-4099 (domestic) and (302) 709-8337 (international).  After placing the call, please tell the operator you wish to join the ViroPharma investor conference call.  

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing innovative products for physician specialists to enable the support of patients with serious diseases for which there is an unmet medical need, and providing rewarding careers to employees.  ViroPharma commercializes Cinryze® (C1 esterase inhibitor [human]) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE).  ViroPharma commercializes Vancocin®, approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information on ViroPharma's commercial products, please download the package inserts at  ViroPharma currently focuses its drug development activities in diseases including C1 esterase inhibitor deficiency and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, The company encourages investors to consult these sections for more information on ViroPharma and our business.

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ViroPharma Initiates Phase 2 Study of C1 Esterase Inhibitor [Human] for Treatment of Antibody-Mediated Rejection (AMR)
2. ViroPharma Launches HAE and Me, A New Online Community to Unite People Living With Hereditary Angioedema
3. ViroPharma Announces Positive CHMP Opinion for Cinryze® (C1 Inhibitor [Human]) in European Union
4. ViroPharma Announces Securities Repurchase Program
5. ViroPharma to Participate in Two March Healthcare Conferences
6. ViroPharma to Release 2010 Fourth Quarter and Full Year Financial Results on February 24, 2011
7. ViroPharma to Participate in Several Upcoming Healthcare Investor Conferences
8. ViroPharma Receives Complete Response Letter for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Supplement
9. ViroPharma to Release 2010 Third Quarter Financial Results on October 27, 2010
10. ViroPharma to Present at the Jefferies 2010 Global Healthcare Conference
11. ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study
Post Your Comments:
(Date:11/30/2015)... Calif. , Nov. 30, 2015 /PRNewswire/ ... the norm in U.S. medical imaging is ... increasingly popular accountable care payer-provider contracts are ... and, in their wake, alter provider-vendor relationships. ... payments will push forward new purchasing frameworks ...
(Date:11/30/2015)... JERUSALEM , Nov. 30, 2015 Oramed ... company focused on the development of oral drug delivery ... investment agreements valued at up to $50,000,000 with Hefei Tianhui Incubator of ... Oramed,s oral insulin capsule, ORMD-0801, in China ... Macau . The agreements were signed ...
(Date:11/30/2015)... N.H. , Nov. 30, 2015 ... that it will feature its latest solutions for ... early identification of cancer at the Radiological Society ... Chicago from November 29 ... recent product advances including iReveal®, an automated breast ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... 30, 2015 , ... California-based i2i Systems, a pioneer defining ... Michigan-based Family Health Center (FHC) has selected i2iTracks as their population health management ... the largest Affordable Care Act grant for Federally Qualified Health Centers in the ...
(Date:11/30/2015)... (PRWEB) , ... November 30, ... ... two new additions to its industry-leading suite of automated breast density assessment ... North America (RSNA) meeting, November 29-December 4, 2015 (South Hall booth #2377). ...
(Date:11/30/2015)... New York, New York (PRWEB) , ... November 30, 2015 , ... ... at the Greater New York Dental Meeting. Their Ecosystem empowers dentists to make complex ... Dentists who visit the booth will receive a free fee survey with 10 procedures ...
(Date:11/30/2015)... ... 2015 , ... Scott Newman MD, FACS of New York’s ... surgeons in the New York City area to utilize the new, non-invasive SculpSure™ ... laser treatment for fat loss in the abdomen, flanks, and other areas that ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... healthcare professionals worldwide today released the results of a survey of educational needs ... and Africa found a growing global demand for high quality online and face-to-face ...
Breaking Medicine News(10 mins):